Zydus Cadila gets DCGI nod for launch of its NCE for diabetes

Cadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes for launch in the country.
     
Drug Controller General of India (DCGI) has approved Lipaglyn to be used for treating 'diabetic dyslipidemeia' for launch, the company said in a filing to BSE.
     
Commenting on the development Zydus Cadila Chairman and Manging Director Pankaj R Patel said: "Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control."

     
 

It has always been our dream to take a molecule right from concept stage to its launch. Today we have realised this dream, he added.
     
Diabetic dyslipidemeia is a condition where a person is diabetic and has elevated levels of total cholesterol.
     
Shares of Cadila healthcare were today trading at Rs 780.85 per scrip in the afternoon trade on BSE, down 4.13% from its previous close.